Clinical trials: Non-ST Elevation Myocardial Infarction
Acute Coronary Syndromes, STEMI
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
- Trial name
- SAPT-ACS (NCT07684742)
- Testing
- Early P2Y12 Inhibitor Monotherapy, Standard Dual Antiplatelet Therapy
- Where
- South Korea
- Volunteers
- 1,900 people
- Sponsor
- Gyeongsang National University Hospital
ST Segment Elevation Myocardial Infarction, Non-ST Segment Elevation Myocardial Infarction
Cardiac Care Solution for Coronary Disease Follow up
This is a prospective, randomized controlled trial. The aim of the study is to evaluate the impacts of a cardiac post-discharge management solution in the secondary prevention of Coronary Artery Disease (CAD).
- Conditions
- ST Segment Elevation Myocardial Infarction, Non-ST Segment Elevation Myocardial Infarction, Unstable Angina
- Trial name
- BAMA (NCT03565978)
- Testing
- BAMA solution
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline